JP2010524968A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010524968A5 JP2010524968A5 JP2010504262A JP2010504262A JP2010524968A5 JP 2010524968 A5 JP2010524968 A5 JP 2010524968A5 JP 2010504262 A JP2010504262 A JP 2010504262A JP 2010504262 A JP2010504262 A JP 2010504262A JP 2010524968 A5 JP2010524968 A5 JP 2010524968A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- adenosine deaminase
- composition according
- tumor
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 23
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 claims 17
- 102000055025 Adenosine deaminases Human genes 0.000 claims 17
- 206010028980 Neoplasm Diseases 0.000 claims 7
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims 6
- 230000000890 antigenic effect Effects 0.000 claims 4
- 229920000642 polymer Polymers 0.000 claims 4
- 101000929500 Bos taurus Adenosine deaminase Proteins 0.000 claims 3
- 239000002202 Polyethylene glycol Substances 0.000 claims 3
- 229920001223 polyethylene glycol Polymers 0.000 claims 3
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims 2
- 229960005305 adenosine Drugs 0.000 claims 2
- 229920000233 poly(alkylene oxides) Polymers 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- 241000283690 Bos taurus Species 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 101000929495 Homo sapiens Adenosine deaminase Proteins 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 239000012736 aqueous medium Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 125000003827 glycol group Chemical group 0.000 claims 1
- 230000012010 growth Effects 0.000 claims 1
- 102000043395 human ADA Human genes 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000007913 intrathecal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 230000003647 oxidation Effects 0.000 claims 1
- 238000007254 oxidation reaction Methods 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91303907P | 2007-04-20 | 2007-04-20 | |
| US60/913,039 | 2007-04-20 | ||
| PCT/US2008/060733 WO2008131163A1 (en) | 2007-04-20 | 2008-04-18 | Enzymatic anticancer therapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010524968A JP2010524968A (ja) | 2010-07-22 |
| JP2010524968A5 true JP2010524968A5 (OSRAM) | 2011-08-04 |
| JP5595904B2 JP5595904B2 (ja) | 2014-09-24 |
Family
ID=39875909
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010504262A Active JP5595904B2 (ja) | 2007-04-20 | 2008-04-18 | 酵素による抗癌治療 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US8741283B2 (OSRAM) |
| EP (1) | EP2147122B1 (OSRAM) |
| JP (1) | JP5595904B2 (OSRAM) |
| KR (1) | KR101540296B1 (OSRAM) |
| CN (1) | CN101680039B (OSRAM) |
| BR (1) | BRPI0810384B8 (OSRAM) |
| CA (1) | CA2684749C (OSRAM) |
| CY (1) | CY1117000T1 (OSRAM) |
| DK (1) | DK2147122T3 (OSRAM) |
| ES (1) | ES2507508T3 (OSRAM) |
| HR (1) | HRP20140947T1 (OSRAM) |
| IL (1) | IL201593A (OSRAM) |
| MX (1) | MX2009011320A (OSRAM) |
| NZ (1) | NZ580980A (OSRAM) |
| PL (1) | PL2147122T3 (OSRAM) |
| PT (1) | PT2147122E (OSRAM) |
| SI (1) | SI2147122T1 (OSRAM) |
| TW (1) | TWI486169B (OSRAM) |
| WO (1) | WO2008131163A1 (OSRAM) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2808389A1 (en) | 2004-11-12 | 2014-12-03 | Asuragen, Inc. | Methods and compositions involving MIRNA and MIRNA inhibitor molecules |
| US8071741B2 (en) | 2007-04-20 | 2011-12-06 | Defiante Farmaceutica, S.A. | Stable recombinant adenosine deaminase |
| CN103476931A (zh) * | 2011-02-03 | 2013-12-25 | 米尔纳医疗股份有限公司 | Mir-34的合成模拟物 |
| EA201700181A1 (ru) | 2014-10-14 | 2017-09-29 | Галозим, Инк. | Композиции аденозиндеаминазы-2 (ада-2), их варианты и способы использования |
| US10874724B2 (en) * | 2015-05-22 | 2020-12-29 | University Of Houston System | Enzymatic immunomodulation of solid tumors and uses thereof |
| CA3056071A1 (en) * | 2016-03-11 | 2017-09-14 | University Of Louisville Research Foundation, Inc. | Methods and compositions for treating tumors |
| EP4317422A3 (en) | 2017-04-13 | 2024-05-01 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
| US10993967B2 (en) | 2018-10-17 | 2021-05-04 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
| US11419898B2 (en) | 2018-10-17 | 2022-08-23 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
| WO2023086931A2 (en) * | 2021-11-12 | 2023-05-19 | Georgia Tech Research Corporation | Adenosine deaminase 1 compositions and methods for using same |
| US20240250753A1 (en) * | 2022-10-10 | 2024-07-25 | Berkeley Marine Robotics Inc. | Ship Hull Inspection using a Swarm of Unmanned Underwater Vehicles equipped with Wireless Laser Systems |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5346823A (en) | 1984-05-29 | 1994-09-13 | Genencor, Inc. | Subtilisin modifications to enhance oxidative stability |
| US5122614A (en) | 1989-04-19 | 1992-06-16 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
| US5324844A (en) | 1989-04-19 | 1994-06-28 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
| US5349001A (en) | 1993-01-19 | 1994-09-20 | Enzon, Inc. | Cyclic imide thione activated polyalkylene oxides |
| US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5605976A (en) | 1995-05-15 | 1997-02-25 | Enzon, Inc. | Method of preparing polyalkylene oxide carboxylic acids |
| US5919455A (en) | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5730990A (en) * | 1994-06-24 | 1998-03-24 | Enzon, Inc. | Non-antigenic amine derived polymers and polymer conjugates |
| US5756593A (en) | 1995-05-15 | 1998-05-26 | Enzon, Inc. | Method of preparing polyalkyene oxide carboxylic acids |
| US6180095B1 (en) | 1997-12-17 | 2001-01-30 | Enzon, Inc. | Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents |
| EP1037649B1 (en) | 1997-12-17 | 2009-09-30 | Enzon, Inc. | Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents |
| US5965119A (en) | 1997-12-30 | 1999-10-12 | Enzon, Inc. | Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents |
| US6624142B2 (en) | 1997-12-30 | 2003-09-23 | Enzon, Inc. | Trimethyl lock based tetrapartate prodrugs |
| US6153655A (en) | 1998-04-17 | 2000-11-28 | Enzon, Inc. | Terminally-branched polymeric linkers and polymeric conjugates containing the same |
| US6824766B2 (en) | 1998-04-17 | 2004-11-30 | Enzon, Inc. | Biodegradable high molecular weight polymeric linkers and their conjugates |
| US6251382B1 (en) | 1998-04-17 | 2001-06-26 | Enzon, Inc. | Biodegradable high molecular weight polymeric linkers and their conjugates |
| US6333396B1 (en) * | 1998-10-20 | 2001-12-25 | Enzon, Inc. | Method for targeted delivery of nucleic acids |
| US20020088017A1 (en) * | 1999-04-28 | 2002-07-04 | Board Of Regents, The University Of Texas System | Adenosine deaminase deficient transgenic mice and methods for the use thereof |
| US6579857B1 (en) | 1999-06-11 | 2003-06-17 | Evanston Northwestern Healthcare Research Institute | Combination cancer therapy comprising adenosine and deaminase enzyme inhibitors |
| AU7868400A (en) | 1999-10-08 | 2001-04-23 | Alza Corporation | Neutral-cationic lipid for nucleic acid and drug delivery |
| AU2001297575A1 (en) | 2000-11-08 | 2002-10-08 | Millennium Pharmaceuticals, Inc. | 38650, 28472, 5495, 65507, 81588 and 14354 methods and compositions of human proteins and uses thereof |
| WO2003045436A1 (en) * | 2001-11-28 | 2003-06-05 | Biopolymed Inc. | Biologically active non-antigenic copolymer and conjugates thereof and methods for producing the same |
| WO2003050241A2 (en) | 2001-12-12 | 2003-06-19 | The Government Of The United States Of America As Represented By The Secretary, Department Of Healthand Human Services | Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to enhance immune response and inflammation |
| US7087229B2 (en) | 2003-05-30 | 2006-08-08 | Enzon Pharmaceuticals, Inc. | Releasable polymeric conjugates based on aliphatic biodegradable linkers |
| US7413738B2 (en) | 2002-08-13 | 2008-08-19 | Enzon Pharmaceuticals, Inc. | Releasable polymeric conjugates based on biodegradable linkers |
| US7122189B2 (en) | 2002-08-13 | 2006-10-17 | Enzon, Inc. | Releasable polymeric conjugates based on aliphatic biodegradable linkers |
| US20040175804A1 (en) * | 2003-03-04 | 2004-09-09 | Skonezny Paul M. | Process for preparing dideoxyinosine using adenosine deaminase enzyme |
| US7301003B2 (en) | 2005-08-26 | 2007-11-27 | Enzon Pharmaceuticals, Inc. | Method of preparing polymers having terminal amine groups |
| US7601798B2 (en) | 2005-10-04 | 2009-10-13 | Enzon Pharmaceuticals, Inc. | Methods of preparing polymers having terminal amine groups using protected amine salts |
| US7989554B2 (en) | 2006-01-10 | 2011-08-02 | Enzon Pharmaceuticals, Inc. | Reacting polyalkylene oxide with base, tertiary alkyl haloacetate, then acid to prepare polyalkylene oxide carboxylic acid |
| CA2653061A1 (en) | 2006-06-21 | 2007-12-27 | Enzon Pharmaceuticals, Inc. | Stabilized proteins |
| CA2662962A1 (en) | 2006-09-15 | 2008-03-20 | Enzon Pharmaceuticals, Inc. | Polyalkylene oxides having hindered ester-based biodegradable linkers |
| TW200835514A (en) | 2006-12-29 | 2008-09-01 | Enzon Pharmaceuticals Inc | Use of adenosine deaminase for treating pulmonary disease |
| US8071741B2 (en) | 2007-04-20 | 2011-12-06 | Defiante Farmaceutica, S.A. | Stable recombinant adenosine deaminase |
-
2008
- 2008-04-18 TW TW097114405A patent/TWI486169B/zh active
- 2008-04-18 JP JP2010504262A patent/JP5595904B2/ja active Active
- 2008-04-18 MX MX2009011320A patent/MX2009011320A/es active IP Right Grant
- 2008-04-18 EP EP08754910.1A patent/EP2147122B1/en active Active
- 2008-04-18 BR BRPI0810384A patent/BRPI0810384B8/pt active IP Right Grant
- 2008-04-18 CA CA2684749A patent/CA2684749C/en not_active Expired - Fee Related
- 2008-04-18 KR KR1020097023239A patent/KR101540296B1/ko active Active
- 2008-04-18 PT PT87549101T patent/PT2147122E/pt unknown
- 2008-04-18 CN CN200880021105.8A patent/CN101680039B/zh active Active
- 2008-04-18 DK DK08754910.1T patent/DK2147122T3/da active
- 2008-04-18 SI SI200831301T patent/SI2147122T1/sl unknown
- 2008-04-18 US US12/105,682 patent/US8741283B2/en active Active
- 2008-04-18 PL PL08754910T patent/PL2147122T3/pl unknown
- 2008-04-18 HR HRP20140947AT patent/HRP20140947T1/hr unknown
- 2008-04-18 ES ES08754910.1T patent/ES2507508T3/es active Active
- 2008-04-18 WO PCT/US2008/060733 patent/WO2008131163A1/en not_active Ceased
- 2008-04-18 NZ NZ580980A patent/NZ580980A/en unknown
-
2009
- 2009-10-18 IL IL201593A patent/IL201593A/en active IP Right Grant
-
2014
- 2014-10-03 CY CY20141100797T patent/CY1117000T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010524968A5 (OSRAM) | ||
| US12296017B2 (en) | Bioorthogonal compositions | |
| Pasut et al. | PEG conjugates in clinical development or use as anticancer agents: an overview | |
| JP6243452B2 (ja) | アルブミン結合アルギニンデイミナーゼ融合たんぱく質を含有する医薬組成物 | |
| JP6666613B2 (ja) | 悪性腫瘍標的ペプチド | |
| ES2371038T3 (es) | Péptidos y derivados peptídicos así como composiciones farmacéuticas que contienen los mismos. | |
| JP2010505444A5 (OSRAM) | ||
| HRP20140947T1 (hr) | Enzimska terapija raka | |
| Vicent | Polymer-drug conjugates as modulators of cellular apoptosis | |
| US20190314523A1 (en) | Tumor-targeting synthetic adenoviruses and uses thereof | |
| Shamay et al. | Assessing the therapeutic efficacy of VEGFR-1-targeted polymer drug conjugates in mouse tumor models | |
| US20210363224A1 (en) | IL13Ra2 PEPTIDE AND ITS USES | |
| US20220040109A1 (en) | Kidney-targeting drug delivery carrier | |
| JP7133225B2 (ja) | 治療用多標的コンストラクトおよびその使用 | |
| Peng et al. | Synthesis and activity of tumor-homing peptide iRGD and histone deacetylase inhibitor valproic acid conjugate | |
| EP3059243A1 (en) | Yap protein inhibiting polypeptide and application thereof | |
| US9987241B2 (en) | Enzyme conjugate and prodrug cancer therapy | |
| JP7357292B2 (ja) | 癌治療用ペプチド | |
| Tao et al. | Multivalent assembly of nucleolin-targeted F3 peptide potentiates TRAIL's tumor penetration and antitumor effects | |
| US12454551B2 (en) | Peptides as inhibitors of fibrotic matrix accumulation | |
| CA3245483A1 (en) | Fusion Proteins and Their Uses | |
| EP4351618A2 (en) | Trem-2/dap-12 inhibitors for treating lung disease and injury and combinations thereof | |
| CN116390768A (zh) | 具有抗癌活性的免疫调节蛋白-siRNA复合物 | |
| US20220362278A1 (en) | Renal targeting-type drug delivery carrier having excellent biodegrability | |
| Trepel et al. | 275. A Heterotypic Bystander Effect Observed for Tumor Cell Killing after AAVP-Mediated Vascular-Targeted Suicide Gene Transfer |